Skip to main content
Home
Online First
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Online First
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Biosimilars
Evaluation of Real-World Cost-Savings and Utilization of Biosimilar Drugs in a Community-Based Oncology Practice
Read More
Biosimilars
Utilization and Clinical Characteristics for the Trastuzumab Originator, Biosimilars, and Other HER2 Inhibitors
Read More
Biosimilars
Cost-Savings from Conversion to Biosimilar Pegfilgrastim-cbqv Allowed Budget-Neutral Expanded Access to Antineoplastic Therapy
Read More
Biosimilars
2021 in Review
Read More
Biosimilars
Bioequivalence of Bevacizumab Reference and Its Biosimilar BCD-021 in Nonsquamous NSCLC
Read More
Biosimilars
Five-Year Follow-Up of a Comparative Phase 3 Study of SB3 and Trastuzumab Reference in HER2-Positive Early or Locally Advanced Breast Cancer
Read More
Biosimilars
Comparative Analysis of Safety, Efficacy, and Immunogenicity of Trastuzumab Reference and Its Biosimilar TX05 in HER2-Positive Early Breast Cancer
Read More
Biosimilars
Oncologists’ Knowledge and Perspectives on the Use of Biosimilars
Read More
Biosimilars
A Successful Model of Biosimilar Adoption in a Community Oncology Practice
Read More
Biosimilars
Real-World Trends in Biosimilar Prescribing Among Oncology Providers
Read More
1
2
3
Page 2 of 3
Results 11 - 20 of 29